Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 651

1.

Phase 1b study of obinutuzumab, ibrutinib, and venetoclax in relapsed and refractory chronic lymphocytic leukemia.

Rogers KA, Huang Y, Ruppert AS, Awan FT, Heerema NA, Hoffman C, Lozanski G, Maddocks KJ, Moran ME, Reid MA, Lucas M, Woyach JA, Whitlow WT, Jones JA, Byrd JC.

Blood. 2018 Aug 15. pii: blood-2018-05-853564. doi: 10.1182/blood-2018-05-853564. [Epub ahead of print]

PMID:
30111609
2.

The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter Transformation.

Reiff SD, Mantel R, Smith LL, Greene JT, Muhowski EM, Fabian CA, Goettl VM, Tran M, Harrington BK, Rogers KA, Awan FT, Maddocks K, Andritsos L, Lehman AM, Sampath D, Lapalombella R, Eathiraj S, Abbadessa G, Schwartz B, Johnson AJ, Byrd JC, Woyach JA.

Cancer Discov. 2018 Aug 9. doi: 10.1158/2159-8290.CD-17-1409. [Epub ahead of print]

PMID:
30093506
3.

Cancer-Specific Stress and Trajectories of Psychological and Physical Functioning in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia.

Goyal NG, Maddocks KJ, Johnson AJ, Byrd JC, Westbrook TD, Andersen BL.

Ann Behav Med. 2018 Mar 15;52(4):287-298. doi: 10.1093/abm/kax004.

PMID:
30084895
4.

Ventricular Arrhythmias Following Ibrutinib Initiation for Lymphoid Malignancies.

Guha A, Derbala MH, Zhao Q, Wiczer TE, Woyach JA, Byrd JC, Awan FT, Addison D.

J Am Coll Cardiol. 2018 Aug 7;72(6):697-698. doi: 10.1016/j.jacc.2018.06.002. No abstract available.

PMID:
30072003
5.

Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance).

Byrd JC, Ruppert AS, Heerema NA, Halvorson AE, Hoke E, Smith MR, Godwin JE, Couban S, Fehniger TA, Thirman MJ, Tallman MS, Appelbaum FR, Stone RM, Robinson S, Chang JE, Mandrekar SJ, Larson RA.

Blood Adv. 2018 Jul 24;2(14):1705-1718. doi: 10.1182/bloodadvances.2017015396.

6.

Use of PD-1 (PDCD1) inhibitors for the treatment of Richter syndrome: experience at a single academic centre.

Rogers KA, Huang Y, Dotson E, Lundberg J, Andritsos LA, Awan FT, Woyach JA, Byrd JC.

Br J Haematol. 2018 Jul 20. doi: 10.1111/bjh.15508. [Epub ahead of print] No abstract available.

PMID:
30028000
7.

HSP90 inhibition without heat shock response.

Byrd JC.

Blood. 2018 Jul 19;132(3):241-242. doi: 10.1182/blood-2018-05-850271. No abstract available.

8.

Noncovalent inhibition of C481S Bruton tyrosine kinase by GDC-0853: a new treatment strategy for ibrutinib-resistant CLL.

Reiff SD, Muhowski EM, Guinn D, Lehman A, Fabian CA, Cheney C, Mantel R, Smith L, Johnson AJ, Young WB, Johnson AR, Liu L, Byrd JC, Woyach JA.

Blood. 2018 Sep 6;132(10):1039-1049. doi: 10.1182/blood-2017-10-809020. Epub 2018 Jul 17.

PMID:
30018078
9.

Ten-year outcome of patients with acute myeloid leukemia not treated with allogeneic transplantation in first complete remission.

Vasu S, Kohlschmidt J, Mrózek K, Eisfeld AK, Nicolet D, Sterling LJ, Becker H, Metzeler KH, Papaioannou D, Powell BL, Kolitz JE, Moore JO, Baer MR, Roboz GJ, Stone RM, Byrd JC, Carroll AJ, Bloomfield CD.

Blood Adv. 2018 Jul 10;2(13):1645-1650. doi: 10.1182/bloodadvances.2017015222.

10.

Use of a comprehensive frailty assessment to predict morbidity in patients with multiple myeloma undergoing transplant.

Rosko AE, Huang Y, Benson DM, Efebera YA, Hofmeister C, Jaglowski S, Devine S, Bhatt G, Wildes TM, Dyko A, Jones D, Naughton MJ, Byrd JC, Burd CE.

J Geriatr Oncol. 2018 Jul 5. pii: S1879-4068(18)30157-7. doi: 10.1016/j.jgo.2018.05.015. [Epub ahead of print]

PMID:
29983352
11.

Evaluation of 230 patients with relapsed/refractory deletion 17p chronic lymphocytic leukaemia treated with ibrutinib from 3 clinical trials.

Jones J, Mato A, Coutre S, Byrd JC, Furman RR, Hillmen P, Osterborg A, Tam C, Stilgenbauer S, Wierda WG, Heerema NA, Eckert K, Clow F, Zhou C, Chu AD, James DF, O'Brien SM.

Br J Haematol. 2018 Aug;182(4):504-512. doi: 10.1111/bjh.15421. Epub 2018 Jun 5.

12.

NF1 mutations are recurrent in adult acute myeloid leukemia and confer poor outcome.

Eisfeld AK, Kohlschmidt J, Mrózek K, Mims A, Walker CJ, Blachly JS, Nicolet D, Orwick S, Maharry SE, Carroll AJ, Powell BL, Kolitz JE, Wang ES, Stone RM, de la Chapelle A, Byrd JC, Bloomfield CD.

Leukemia. 2018 Jun 5. doi: 10.1038/s41375-018-0147-4. [Epub ahead of print]

PMID:
29872168
13.

Anti-leukemic effects of all-trans retinoic acid in combination with Daratumumab in acute myeloid leukemia.

Buteyn NJ, Fatehchand K, Santhanam R, Fang H, Dettorre GM, Gautam S, Harrington BK, Henderson SE, Merchand-Reyes G, Mo X, Benson DM, Carson WE 3rd, Vasu S, Byrd JC, Butchar JP, Tridandapani S.

Int Immunol. 2018 Jul 24;30(8):375-383. doi: 10.1093/intimm/dxy040.

PMID:
29868798
14.

Changes in clinical stage identify patients with CLL and different outcome within iwCLL partial response: RESONATE study.

Moreno C, Delgado J, Byrd JC, Zvagelsky WL, Suzuki S, Hsu E, James DF, Montserrat E.

Br J Haematol. 2018 May 31. doi: 10.1111/bjh.15397. [Epub ahead of print] No abstract available.

PMID:
29855051
15.

Targeting the C481S Ibrutinib-Resistance Mutation in Bruton's Tyrosine Kinase Using PROTAC-Mediated Degradation.

Buhimschi AD, Armstrong HA, Toure M, Jaime-Figueroa S, Chen TL, Lehman AM, Woyach JA, Johnson AJ, Byrd JC, Crews CM.

Biochemistry. 2018 Jul 3;57(26):3564-3575. doi: 10.1021/acs.biochem.8b00391. Epub 2018 Jun 14.

PMID:
29851337
16.

The interleukin-3 receptor CD123 targeted SL-401 mediates potent cytotoxic activity against CD34+CD123+ cells from acute myeloid leukemia/myelodysplastic syndrome patients and healthy donors.

Mani R, Goswami S, Gopalakrishnan B, Ramaswamy R, Wasmuth R, Tran M, Mo X, Gordon A, Bucci D, Lucas DM, Mims A, Brooks C, Dorrance A, Walker A, Blum W, Byrd JC, Lozanski G, Vasu S, Muthusamy N.

Haematologica. 2018 Aug;103(8):1288-1297. doi: 10.3324/haematol.2018.188193. Epub 2018 May 17.

17.

Cells, cytokines, chemokines, and cancer stress: A biobehavioral study of patients with chronic lymphocytic leukemia.

Andersen BL, Goyal NG, Weiss DM, Westbrook TD, Maddocks KJ, Byrd JC, Johnson AJ.

Cancer. 2018 Aug 1;124(15):3240-3248. doi: 10.1002/cncr.31538. Epub 2018 May 14.

PMID:
29757455
18.

Novel role of prostate apoptosis response-4 tumor suppressor in B-cell chronic lymphocytic leukemia.

McKenna MK, Noothi SK, Alhakeem SS, Oben KZ, Greene JT, Mani R, Perry KL, Collard JP, Rivas JR, Hildebrandt GC, Fleischman RA, Durbin EB, Byrd JC, Wang C, Muthusamy N, Rangnekar VM, Bondada S.

Blood. 2018 Jun 28;131(26):2943-2954. doi: 10.1182/blood-2017-10-813931. Epub 2018 Apr 25.

PMID:
29695515
19.

Frequency and impact of grade three or four toxicities of novel agents on outcomes of older patients with chronic lymphocytic leukemia and non-Hodgkin lymphoma (alliance A151611).

Tallarico M, Foster JC, Seisler D, Lafky JM, Hurria A, Jatoi A, Cohen HJ, Muss HB, Bartlett N, Cheson BD, Jung SH, Leonard JP, Byrd JC, Nabhan C.

J Geriatr Oncol. 2018 Jul;9(4):321-328. doi: 10.1016/j.jgo.2018.03.018. Epub 2018 Apr 17.

20.

A novel regimen for relapsed/refractory adult acute myeloid leukemia using a KMT2A partial tandem duplication targeted therapy: results of phase 1 study NCI 8485.

Mims AS, Mishra A, Orwick S, Blachly J, Klisovic RB, Garzon R, Walker AR, Devine SM, Walsh KJ, Vasu S, Whitman S, Marcucci G, Jones D, Heerema NA, Lozanski G, Caligiuri MA, Bloomfield CD, Byrd JC, Piekarz R, Grever MR, Blum W.

Haematologica. 2018 Jun;103(6):982-987. doi: 10.3324/haematol.2017.186890. Epub 2018 Mar 22.

21.

Mutation patterns identify adult patients with de novo acute myeloid leukemia aged 60 years or older who respond favorably to standard chemotherapy: an analysis of Alliance studies.

Eisfeld AK, Kohlschmidt J, Mrózek K, Blachly JS, Walker CJ, Nicolet D, Orwick S, Maharry SE, Carroll AJ, Stone RM, de la Chapelle A, Wang ES, Kolitz JE, Powell BL, Byrd JC, Bloomfield CD.

Leukemia. 2018 Jun;32(6):1338-1348. doi: 10.1038/s41375-018-0068-2. Epub 2018 Feb 25.

22.

First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL.

Byrd JC, Smith S, Wagner-Johnston N, Sharman J, Chen AI, Advani R, Augustson B, Marlton P, Renee Commerford S, Okrah K, Liu L, Murray E, Penuel E, Ward AF, Flinn IW.

Oncotarget. 2018 Jan 22;9(16):13023-13035. doi: 10.18632/oncotarget.24310. eCollection 2018 Feb 27.

23.

iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL.

Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H, Hillmen P, Keating M, Montserrat E, Chiorazzi N, Stilgenbauer S, Rai KR, Byrd JC, Eichhorst B, O'Brien S, Robak T, Seymour JF, Kipps TJ.

Blood. 2018 Jun 21;131(25):2745-2760. doi: 10.1182/blood-2017-09-806398. Epub 2018 Mar 14. Review.

PMID:
29540348
24.

Prognostic Factors for Complete Response to Ibrutinib in Patients With Chronic Lymphocytic Leukemia: A Pooled Analysis of 2 Clinical Trials.

O'Brien SM, Jaglowski S, Byrd JC, Bannerji R, Blum KA, Fox CP, Furman RR, Hillmen P, Kipps TJ, Montillo M, Sharman J, Suzuki S, James DF, Chu AD, Coutre SE.

JAMA Oncol. 2018 May 1;4(5):712-716. doi: 10.1001/jamaoncol.2017.5604.

25.

Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience.

O'Brien S, Furman RR, Coutre S, Flinn IW, Burger JA, Blum K, Sharman J, Wierda W, Jones J, Zhao W, Heerema NA, Johnson AJ, Luan Y, James DF, Chu AD, Byrd JC.

Blood. 2018 Apr 26;131(17):1910-1919. doi: 10.1182/blood-2017-10-810044. Epub 2018 Feb 2.

26.

Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness.

Czuczman MS, Leonard JP, Jung S, Johnson JL, Hsi ED, Byrd JC, Cheson BD.

Ann Oncol. 2018 Jan 29. doi: 10.1093/annonc/mdx812. [Epub ahead of print] No abstract available.

PMID:
29390097
27.

BRD4 Profiling Identifies Critical Chronic Lymphocytic Leukemia Oncogenic Circuits and Reveals Sensitivity to PLX51107, a Novel Structurally Distinct BET Inhibitor.

Ozer HG, El-Gamal D, Powell B, Hing ZA, Blachly JS, Harrington B, Mitchell S, Grieselhuber NR, Williams K, Lai TH, Alinari L, Baiocchi RA, Brinton L, Baskin E, Cannon M, Beaver L, Goettl VM, Lucas DM, Woyach JA, Sampath D, Lehman AM, Yu L, Zhang J, Ma Y, Zhang Y, Spevak W, Shi S, Severson P, Shellooe R, Carias H, Tsang G, Dong K, Ewing T, Marimuthu A, Tantoy C, Walters J, Sanftner L, Rezaei H, Nespi M, Matusow B, Habets G, Ibrahim P, Zhang C, Mathé EA, Bollag G, Byrd JC, Lapalombella R.

Cancer Discov. 2018 Apr;8(4):458-477. doi: 10.1158/2159-8290.CD-17-0902. Epub 2018 Jan 31.

PMID:
29386193
28.

Nitric Oxide Production by Myeloid-Derived Suppressor Cells Plays a Role in Impairing Fc Receptor-Mediated Natural Killer Cell Function.

Stiff A, Trikha P, Mundy-Bosse B, McMichael E, Mace TA, Benner B, Kendra K, Campbell A, Gautam S, Abood D, Landi I, Hsu V, Duggan M, Wesolowski R, Old M, Howard JH, Yu L, Stasik N, Olencki T, Muthusamy N, Tridandapani S, Byrd JC, Caligiuri M, Carson WE.

Clin Cancer Res. 2018 Apr 15;24(8):1891-1904. doi: 10.1158/1078-0432.CCR-17-0691. Epub 2018 Jan 23.

PMID:
29363526
29.

BRAFV600E accelerates disease progression and enhances immune suppression in a mouse model of B-cell leukemia.

Tsai YT, Lakshmanan A, Lehman A, Harrington BK, Lucas FM, Tran M, Sass EJ, Long M, Flechtner AD, Jaynes F, La Perle K, Coppola V, Lozanski G, Muthusamy N, Byrd JC, Grever MR, Lucas DM.

Blood Adv. 2017 Oct 30;1(24):2147-2160. doi: 10.1182/bloodadvances.2017006593. eCollection 2017 Nov 14.

30.

Cumulative incidence, risk factors, and management of atrial fibrillation in patients receiving ibrutinib.

Wiczer TE, Levine LB, Brumbaugh J, Coggins J, Zhao Q, Ruppert AS, Rogers K, McCoy A, Mousa L, Guha A, Heerema NA, Maddocks K, Christian B, Andritsos LA, Jaglowski S, Devine S, Baiocchi R, Woyach J, Jones J, Grever M, Blum KA, Byrd JC, Awan FT.

Blood Adv. 2017 Sep 8;1(20):1739-1748. doi: 10.1182/bloodadvances.2017009720. eCollection 2017 Sep 12.

31.

Near-tetraploidy is associated with Richter transformation in chronic lymphocytic leukemia patients receiving ibrutinib.

Miller CR, Ruppert AS, Heerema NA, Maddocks KJ, Labanowska J, Breidenbach H, Lozanski G, Zhao W, Gordon AL, Jones JA, Flynn JM, Jaglowski SM, Andritsos LA, Blum KA, T Awan F, Rogers KA, Grever MR, Johnson AJ, Abruzzo LV, Hertlein EK, Blachly JS, Woyach JA, Byrd JC.

Blood Adv. 2017 Aug 21;1(19):1584-1588. doi: 10.1182/bloodadvances.2017007302. eCollection 2017 Aug 22.

32.

Novel SF3B1 in-frame deletions result in aberrant RNA splicing in CLL patients.

Agrawal AA, Seiler M, Brinton LT, Mantel R, Lapalombella R, Woyach JA, Johnson AJ, Zhu P, Warmuth M, Yu L, Byrd JC, Smith PG, Blachly JS, Buonamici S.

Blood Adv. 2017 Jun 14;1(15):995-1000. doi: 10.1182/bloodadvances.2017007062. eCollection 2017 Jun 27.

33.

Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial.

Jones JA, Mato AR, Wierda WG, Davids MS, Choi M, Cheson BD, Furman RR, Lamanna N, Barr PM, Zhou L, Chyla B, Salem AH, Verdugo M, Humerickhouse RA, Potluri J, Coutre S, Woyach J, Byrd JC.

Lancet Oncol. 2018 Jan;19(1):65-75. doi: 10.1016/S1470-2045(17)30909-9. Epub 2017 Dec 12.

PMID:
29246803
34.

A single-institution retrospective cohort study of first-line R-EPOCH chemoimmunotherapy for Richter syndrome demonstrating complex chronic lymphocytic leukaemia karyotype as an adverse prognostic factor.

Rogers KA, Huang Y, Ruppert AS, Salem G, Stephens DM, Heerema NA, Andritsos LA, Awan FT, Byrd JC, Flynn JM, Maddocks KJ, Jones JA.

Br J Haematol. 2018 Jan;180(2):259-266. doi: 10.1111/bjh.15035. Epub 2017 Nov 28.

PMID:
29193006
35.

Hairy Cell Leukemia, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology.

Wierda WG, Byrd JC, Abramson JS, Bhat S, Bociek G, Brander D, Brown J, Chanan-Khan A, Coutre SE, Davis RS, Fletcher CD, Hill B, Kahl BS, Kamdar M, Kaplan LD, Khan N, Kipps TJ, Lancet J, Ma S, Malek S, Mosse C, Shadman M, Siddiqi T, Stephens D, Wagner N, Zelenetz AD, Dwyer MA, Sundar H.

J Natl Compr Canc Netw. 2017 Nov;15(11):1414-1427. doi: 10.6004/jnccn.2017.0165.

PMID:
29118233
36.

Role and regulation of microRNAs targeting BTK in acute myelogenous leukemia.

Rizzotto L, Lai TH, Bottoni A, Woyach JA, Lapalombella R, Bloomfield CD, Byrd JC, Sampath D.

Leuk Lymphoma. 2018 Jun;59(6):1461-1465. doi: 10.1080/10428194.2017.1376742. Epub 2017 Sep 18. No abstract available.

37.

Spotlight on Ibrutinib in PCNSL: Adding Another Feather to Its Cap.

Lakshmanan A, Byrd JC.

Cancer Discov. 2017 Sep;7(9):940-942. doi: 10.1158/2159-8290.CD-17-0714.

38.

Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials.

Brown JR, Moslehi J, O'Brien S, Ghia P, Hillmen P, Cymbalista F, Shanafelt TD, Fraser G, Rule S, Kipps TJ, Coutre S, Dilhuydy MS, Cramer P, Tedeschi A, Jaeger U, Dreyling M, Byrd JC, Howes A, Todd M, Vermeulen J, James DF, Clow F, Styles L, Valentino R, Wildgust M, Mahler M, Burger JA.

Haematologica. 2017 Oct;102(10):1796-1805. doi: 10.3324/haematol.2017.171041. Epub 2017 Jul 27.

39.

MICA-Expressing Monocytes Enhance Natural Killer Cell Fc Receptor-Mediated Antitumor Functions.

Campbell AR, Duggan MC, Suarez-Kelly LP, Bhave N, Opheim KS, McMichael EL, Trikha P, Parihar R, Luedke E, Lewis A, Yung B, Lee R, Raulet D, Tridandapani S, Groh V, Yu L, Yildiz V, Byrd JC, Caligiuri MA, Carson WE 3rd.

Cancer Immunol Res. 2017 Sep;5(9):778-789. doi: 10.1158/2326-6066.CIR-16-0005. Epub 2017 Jul 19.

40.

Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib.

Turtle CJ, Hay KA, Hanafi LA, Li D, Cherian S, Chen X, Wood B, Lozanski A, Byrd JC, Heimfeld S, Riddell SR, Maloney DG.

J Clin Oncol. 2017 Sep 10;35(26):3010-3020. doi: 10.1200/JCO.2017.72.8519. Epub 2017 Jul 17.

41.

Ibrutinib treatment improves T cell number and function in CLL patients.

Long M, Beckwith K, Do P, Mundy BL, Gordon A, Lehman AM, Maddocks KJ, Cheney C, Jones JA, Flynn JM, Andritsos LA, Awan F, Fraietta JA, June CH, Maus MV, Woyach JA, Caligiuri MA, Johnson AJ, Muthusamy N, Byrd JC.

J Clin Invest. 2017 Aug 1;127(8):3052-3064. doi: 10.1172/JCI89756. Epub 2017 Jul 17.

42.

Circulating myeloid-derived suppressor cells increase in patients undergoing neo-adjuvant chemotherapy for breast cancer.

Wesolowski R, Duggan MC, Stiff A, Markowitz J, Trikha P, Levine KM, Schoenfield L, Abdel-Rasoul M, Layman R, Ramaswamy B, Macrae ER, Lustberg MB, Reinbolt RE, Mrozek E, Byrd JC, Caligiuri MA, Mace TA, Carson WE 3rd.

Cancer Immunol Immunother. 2017 Nov;66(11):1437-1447. doi: 10.1007/s00262-017-2038-3. Epub 2017 Jul 7.

PMID:
28688082
43.

Activation of the FcgammaReceptorIIIa on human natural killer cells leads to increased expression of functional interleukin-21 receptor.

McMichael EL, Courtney NB, Duggan MC, Wesolowski R, Quiroga D, Kondadasula SV, Atwal LS, Bhave N, Luedke E, Jaime-Ramirez AC, Campbell AR, Mo X, Byrd JC, Carson Iii WE.

Oncoimmunology. 2017 May 2;6(5):e1312045. doi: 10.1080/2162402X.2017.1312045. eCollection 2017.

44.

Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL.

Brown JR, Hillmen P, O'Brien S, Barrientos JC, Reddy NM, Coutre SE, Tam CS, Mulligan SP, Jaeger U, Barr PM, Furman RR, Kipps TJ, Cymbalista F, Thornton P, Caligaris-Cappio F, Delgado J, Montillo M, DeVos S, Moreno C, Pagel JM, Munir T, Burger JA, Chung D, Lin J, Gau L, Chang B, Cole G, Hsu E, James DF, Byrd JC.

Leukemia. 2018 Jan;32(1):83-91. doi: 10.1038/leu.2017.175. Epub 2017 Jun 8.

45.

NF-κB p50 (nfkb1) contributes to pathogenesis in the Eμ-TCL1 mouse model of chronic lymphocytic leukemia.

Chen TL, Tran M, Lakshmanan A, Harrington BK, Gupta N, Goettl VM, Lehman AM, Trudeau S, Lucas DM, Johnson AJ, Byrd JC, Hertlein E.

Blood. 2017 Jul 20;130(3):376-379. doi: 10.1182/blood-2017-01-761130. Epub 2017 May 17. No abstract available.

46.

Prognostic and biologic significance of long non-coding RNA profiling in younger adults with cytogenetically normal acute myeloid leukemia.

Papaioannou D, Nicolet D, Volinia S, Mrózek K, Yan P, Bundschuh R, Carroll AJ, Kohlschmidt J, Blum W, Powell BL, Uy GL, Kolitz JE, Wang ES, Eisfeld AK, Orwick SJ, Lucas DM, Caligiuri MA, Stone RM, Byrd JC, Garzon R, Bloomfield CD.

Haematologica. 2017 Aug;102(8):1391-1400. doi: 10.3324/haematol.2017.166215. Epub 2017 May 4.

47.

BTKC481S-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia.

Woyach JA, Ruppert AS, Guinn D, Lehman A, Blachly JS, Lozanski A, Heerema NA, Zhao W, Coleman J, Jones D, Abruzzo L, Gordon A, Mantel R, Smith LL, McWhorter S, Davis M, Doong TJ, Ny F, Lucas M, Chase W, Jones JA, Flynn JM, Maddocks K, Rogers K, Jaglowski S, Andritsos LA, Awan FT, Blum KA, Grever MR, Lozanski G, Johnson AJ, Byrd JC.

J Clin Oncol. 2017 May 1;35(13):1437-1443. doi: 10.1200/JCO.2016.70.2282. Epub 2017 Feb 13.

48.

Use of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia treated with single-agent ibrutinib.

Jones JA, Hillmen P, Coutre S, Tam C, Furman RR, Barr PM, Schuster SJ, Kipps TJ, Flinn IW, Jaeger U, Burger JA, Cheng M, Ninomoto J, James DF, Byrd JC, O'Brien SM.

Br J Haematol. 2017 Jul;178(2):286-291. doi: 10.1111/bjh.14660. Epub 2017 Apr 10.

49.

Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL.

Barr PM, Brown JR, Hillmen P, O'Brien S, Barrientos JC, Reddy NM, Coutre S, Mulligan SP, Jaeger U, Furman RR, Cymbalista F, Montillo M, Dearden C, Robak T, Moreno C, Pagel JM, Burger JA, Suzuki S, Sukbuntherng J, Cole G, James DF, Byrd JC.

Blood. 2017 May 11;129(19):2612-2615. doi: 10.1182/blood-2016-12-737346. Epub 2017 Apr 3.

50.

PLCG2 C2 domain mutations co-occur with BTK and PLCG2 resistance mutations in chronic lymphocytic leukemia undergoing ibrutinib treatment.

Jones D, Woyach JA, Zhao W, Caruthers S, Tu H, Coleman J, Byrd JC, Johnson AJ, Lozanski G.

Leukemia. 2017 Jul;31(7):1645-1647. doi: 10.1038/leu.2017.110. Epub 2017 Apr 3. No abstract available.

PMID:
28366935

Supplemental Content

Support Center